always be available and then marker combinations from primary disease have to be employed. In this context, it would be helpful to communicate data on stability of marker combinations at initial diagnosis and at relapse. Furthermore, the number of marker combinations used for MRD quantification should be mentioned.
We thank von Stackelberg et al 1 for their comments. We agree that minimal residual disease (MRD) is emerging as a reliable predictor of outcome in children with first relapse ALL, although some fine tuning to define the optimal time points and cutoff levels to use in each protocol may be necessary. In our series 2 , MRD at the end of remission induction was particularly informative in patients who relapsed off-therapy; in our current protocol for first relapse ALL, patients with 'high risk' features are candidates for transplant irrespective of MRD findings. This is in line with the BFM concepts mentioned by von Stackelberg et al.
To monitor MRD, we use markers selected from those expressed by the leukemic cells of each patient, akin to the selection of suitable primers for PCR assays. This tailor-made strategy increases the reliability of the assay and ensures that negative findings are not due to the lack of aberrant phenotypes in the leukemic cells. Among the 35 patients monitored for MRD in our study, optimal phenotypes were selected at first relapse in 32, including two with 'isolated' extramedullary relapse: in one of these patients, we analyzed leukemic cells recovered from the spinal fluid; in the other patient, we analyzed those detected by flow cytometry in the bone marrow (which was in morphological remission). Cells were not available at the time of first relapse in only three patients. According to the phenotype determined at diagnosis, one of these patients had MRD at day 36. Of the remaining two patients, both with extramedullary relapse as the first event and MRD-negative at day 36, one had a second extramedullary relapse, with cells retaining the phenotype observed at diagnosis; the other remains in remission. Overall, the immunophenotypes used to monitor MRD were retained in all 14 patients tested at the time of second relapse, including three of the group with undetectable MRD at day 36 (see page 501, second paragraph of Coustan-Smith et al 2, 8 ). To prevent the possibility of phenotypic shift, we always recommend the use of multiple marker combinations whenever possible. [3] [4] [5] [6] Likewise, more than one allele-specific oligonucleotide probe should be used with PCR to offset the risk of false-negative results due to oligoclonality and clonal evolution. 7 Regarding the sensitivity of flow cytometry, one should make a distinction between flow cytometric techniques that rely on combinations that are not expressed by normal hematopoietic cells (including hematogones) and those that use marker combinations that are not completely leukemia specific. We use the former strategy, which is guided by a large number of normal and regenerating reference samples, 5 and yields reliable and clinically useful information. 3, 8, 9 At our institution, both flow cytometry and PCR have been applied in tandem to select postremission therapies in childhood ALL since 1998; we have found a high degree of concordance between the two methods. 10 In our experience, flow cytometry can be at least as specific as PCR if one uses proper markers and techniques, and is satisfied with a 10 À4 limit of detection.
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